Display options
Cite
Selmanovic K, Zec SL, Vanis N, et al. UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Mater Sociomed. 2016;28(2):116-20doi: 10.5455/msm.2016.28.116-120.
Selmanovic, K., Zec, S. L., Vanis, N., Zecevic, L., Setkic, M., Rasic, A., & Zerem, E. (2016). UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Materia socio-medica, 28(2), 116-20. https://doi.org/10.5455/msm.2016.28.116-120
Selmanovic, Kenan, et al. "UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015." Materia socio-medica vol. 28,2 (2016): 116-20. doi: https://doi.org/10.5455/msm.2016.28.116-120
Selmanovic K, Zec SL, Vanis N, Zecevic L, Setkic M, Rasic A, Zerem E. UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015. Mater Sociomed. 2016 Apr;28(2):116-20. doi: 10.5455/msm.2016.28.116-120. Epub 2016 Mar 25. PMID: 27147917; PMCID: PMC4851497.
Copy Download .nbib Format: NLM
Share it on

Mater Sociomed. 2016 Apr;28(2):116-20. doi: 10.5455/msm.2016.28.116-120. Epub 2016 Mar 25.

UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.

Materia socio-medica

Kenan Selmanovic, Svjetlana Loga Zec, Nenad Vanis, Lamija Zecevic, Manja Setkic, Azra Rasic, Enver Zerem

Affiliations

  1. Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  2. Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  3. Department of Gastroenterology and Hepatology, Clinical Centre of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
  4. Institute of Clinical Immunology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  5. Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  6. Institute of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  7. Department of Gastroenterology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.

PMID: 27147917 PMCID: PMC4851497 DOI: 10.5455/msm.2016.28.116-120

Abstract

OBJECTIVE: Expenditures for drugs are increasingly burdening already insufficient funds for health protection. This is especially evident in less developed European countries such as Bosnia and Herzegovina. The question is whether such analyses can help save funds for financing treatment for diseases, with an emphasis on a more rational choice of drug for appropriate indication, whereby clinical complications of hypertension would be prevented and patients would have quality of their lives improved.

AIM: Focus of research has been set on analysis of use of antihypertensive drugs in Bosnia and Herzegovina in the time-period January 2013-March 2015. Use of all drugs for treatment of hypertension in that time-period in the country has been shown in an unbiased manner.

METHODS: The study is designed as retrospective-prospective comparative research of use of antihypertensive drugs in BiH in a certain time-period. Data are collected from relevant drug utilisation database which has been established in Bosnia and Herzegovina since 2013.

RESULTS: We have calculated financial expenditure for prescribed antihypertensives in the time- period of 2013, 2014 and Q1 2015. Use of antihypertensives at the country level for this time-period is BAM 200,242,218. At the country level, physicians are most often opting for combination therapy: ACE inhibitors + diuretics (20.2%) and ACE inhibitors + Ca channel antagonists (18.0%).

CONCLUSION: In this research, it has been shown that modern drugs are used for treatment of hypertension in Bosnia and Herzegovina. These drugs are used in the same order as they are prescribed in developed countries.

Keywords: antihypertensive drugs; hypertension; pharmacoeconomics; rational therapy

References

  1. Lancet. 2005 Jan 15-21;365(9455):217-23 - PubMed
  2. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S92-8 - PubMed
  3. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):412-21 - PubMed
  4. Drug Saf. 2014 Mar;37(3):127-34 - PubMed
  5. Orv Hetil. 2015 Apr 19;156(16):623-5 - PubMed
  6. J Hypertens. 2007 Sep;25(9):1751-62 - PubMed
  7. Profiles Drug Subst Excip Relat Methodol. 2015;40:371-429 - PubMed
  8. JAMA. 2014 Feb 5;311(5):507-20 - PubMed
  9. Vnitr Lek. 2015 May;61(5):458-65 - PubMed
  10. Am Fam Physician. 2008 May 1;77(9):1279-86 - PubMed
  11. Am J Health Syst Pharm. 2014 Mar 15;71(6):482-99 - PubMed
  12. Kidney Int Suppl (2011). 2013 Dec;3(4):343-345 - PubMed

Publication Types